Cardiovascular Effects of Glucagonlike peptide-1 AgonistsDAVIDSON, Michael H.The American journal of cardiology. 2011, Vol 108, Num 3, issn 0002-9149, 33B-41B, SUPArticle

Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndromeDAVIDSON, Michael H.The American journal of cardiology. 2004, Vol 93, Num 11A, pp 3C-11C, issn 0002-9149, SUPConference Paper

Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acidsDAVIDSON, Michael H.The American journal of cardiology. 2006, Vol 98, Num 4, issn 0002-9149, 27i-33i, SUPArticle

Combination therapy for dyslipidemia: Safety and regulatory considerationsDAVIDSON, Michael H.The American journal of cardiology. 2002, Vol 90, Num 10B, pp 50K-60K, issn 0002-9149Conference Paper

Reducing residual risk for patients on statin therapy : The potential role of combination therapyDAVIDSON, Michael H.The American journal of cardiology. 2005, Vol 96, Num 9A, pp 3K-13K, issn 0002-9149, SUPConference Paper

Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive CardiologistDAVIDSON, Michael H.The American journal of cardiology. 2012, Vol 110, Num 9, issn 0002-9149, B43-B49, SUPArticle

Cardio-Diabetes: Special Considerations for the Patient with Diabetes and Cardiovascular DiseaseDAVIDSON, Michael H.The American journal of cardiology. 2012, Vol 110, Num 9, issn 0002-9149, 75 p., SUPSerial Issue

Safety profiles for the HMG-CoA reductase inhibitors: Treatment and trustDAVIDSON, Michael H.Drugs (Basel). 2001, Vol 61, Num 2, pp 197-206, issn 0012-6667Article

HIGH-DENSITY LIPOPROTEIN AS A THERAPEUTIC TARGET: THE NEXT FRONTIER IN CORONARY ARTERY DISEASE RISK REDUCTIONDAVIDSON, Michael H.The American journal of cardiology. 2009, Vol 104, Num 10A, issn 0002-9149, 64 p., SUPSerial Issue

Advances in the Detection of Rupture-Prone Plaque: The Role of Lipoprotein-Associated Phospholipase A₂ in Cardiovascular Risk AssessmentDAVIDSON, Michael H.The American journal of cardiology. 2008, Vol 101, Num 12A, issn 0002-9149, 59 p., SUPSerial Issue

Omega-3 Fatty Acids and Cardiovascular Disease ReductionDAVIDSON, Michael H.The American journal of cardiology. 2006, Vol 98, Num 4, issn 0002-9149, 81 p., SUPSerial Issue

A symposium: combination therapy for dyslipidemia in the metabolic syndromeDAVIDSON, Michael H.The American journal of cardiology. 2005, Vol 96, Num 9A, issn 0002-9149, 73 p., SUPConference Proceedings

Apolipoprotein Measurements: Is More Widespread Use Clinically Indicated?DAVIDSON, Michael H.Clinical cardiology (Mahwah, NJ). 2009, Vol 32, Num 9, pp 482-486, issn 0160-9289, 5 p.Article

Rosuvastatin in elderly patientsDAVIDSON, Michael H.Drugs & aging. 2007, Vol 24, Num 11, pp 933-944, issn 1170-229X, 12 p.Article

A symposium: Emerging strategies for the prevention and treatment of atherosclerosis in patients with type 2 diabetes mellitus and the metabolic syndromeDAVIDSON, Michael H.The American journal of cardiology. 2004, Vol 93, Num 11A, issn 0002-9149, 55 p., SUPConference Proceedings

A symposium: Utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agentsDAVIDSON, Michael H.The American journal of cardiology. 2001, Vol 87, Num 4A, issn 0002-9149, 43 p.Conference Proceedings

A symposium: national cholesterol education program adult treatment panel III: impact and implementation of the new guidelinesDAVIDSON, Michael H.The American journal of cardiology. 2002, Vol 89, Num 5A, issn 0002-9149, 60 p.Conference Proceedings

A symposium: combination therapy for dyslipidemiaDAVIDSON, Michael H.The American journal of cardiology. 2002, Vol 90, Num 10B, issn 0002-9149, 62 p.Conference Proceedings

Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical TrialsDEEDWANIA, Prakash; SINGH, Vibhuti; DAVIDSON, Michael H et al.The American journal of cardiology. 2009, Vol 104, Num 10A, issn 0002-9149, 3E-9E, SUPArticle

Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next FrontierDAVIDSON, Michael H; ROSENSON, Robert S.The American journal of cardiology. 2009, Vol 104, Num 10A, issn 0002-9149, 52E-57E, SUPArticle

Pharmacokinetic interactions between statins and fibratesCORSINI, Alberto; BELLOSTA, Stefano; DAVIDSON, Michael H et al.The American journal of cardiology. 2005, Vol 96, Num 9A, pp 44K-49K, issn 0002-9149, SUPConference Paper

Niacin Use and Cutaneous Flushing : Mechanisms and Strategies for PreventionDAVIDSON, Michael H.The American journal of cardiology. 2008, Vol 101, Num 8A, issn 0002-9149, 14B-19B, SUPArticle

Combination therapy for elevated low-density lipoprotein cholesterol: The key to coronary artery disease risk reductionMCKENNEY, Jim.The American journal of cardiology. 2002, Vol 90, Num 10B, pp 8K-20K, issn 0002-9149Conference Paper

Coronary calcium on electron beam tomography imaging as a surrogate marker of coronary artery diseaseRAGGI, Paolo.The American journal of cardiology. 2001, Vol 87, Num 4A, pp 27A-34A, issn 0002-9149Conference Paper

The Cardiovascular Risk Continuum from Pre-Diabetes to Diabetes: The Role of the Cardiologist in Therapeutic Intervention to Alter the Disease ProcessDAVIDSON, Michael H; PLUTZKY, Jorge.The American journal of cardiology. 2011, Vol 108, Num 3, issn 0002-9149, 71 p., SUPSerial Issue